Bivalent Domain Resolution Failure at Neurodevelopment Genes

Target: Bivalent Domain Resolution Composite Score: 0.410 Price: $0.44▲8.3% Citation Quality: Pending neurodegeneration Status: proposed
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
📄 Export → LaTeX
Select venue
arXiv Preprint NeurIPS Nature Methods PLOS ONE
🌐 Open in Overleaf →
📖 Export BibTeX
⚠ Thin Description⚠ Low Validation Senate Quality Gates →
Evidence Strength Pending (0%)
5
Citations
1
Debates
5
Supporting
2
Opposing
Quality Report Card click to collapse
C
Composite: 0.410
Top 82% of 1875 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
C Mech. Plausibility 15% 0.40 Top 91%
C+ Evidence Strength 15% 0.50 Top 57%
C+ Novelty 12% 0.50 Top 82%
C Feasibility 12% 0.45 Top 78%
C+ Impact 12% 0.50 Top 84%
C Druggability 10% 0.40 Top 81%
D Safety Profile 8% 0.30 Top 92%
D Competition 6% 0.35 Top 95%
D Data Availability 5% 0.35 Top 94%
D Reproducibility 5% 0.35 Top 89%
Evidence
5 supporting | 2 opposing
Citation quality: 0%
Debates
1 session A+
Avg quality: 1.00
Convergence
0.00 F 30 related hypothesis share this target

From Analysis:

Comparative epigenetic signatures: DNA methylation age acceleration and histone modifications across AD, PD, and ALS

Investigate shared DNA methylation age acceleration and histone modification patterns (H3K27me3, H3K4me3, H3K9me3, acetylation) across Alzheimer disease, Parkinson disease, and ALS. Identify common epigenetic signatures that distinguish these neurodegenerative diseases from normal aging.

→ View full analysis & debate transcript

Description

Bivalent Domain Resolution Failure at Neurodevelopment Genes

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Bivalent Domain Resolution
Hypothesis Target"] B["Pathway Dysregulation
Cited Mechanism"] C["Cellular Response
Stress or Clearance Change"] D["Neural Circuit Effect
Synapse/Glia Vulnerability"] E["Neurodegeneration
Disease-Relevant Outcome"] A --> B B --> C C --> D D --> E style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7 style B fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style E fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.40 (15%) Evidence 0.50 (15%) Novelty 0.50 (12%) Feasibility 0.45 (12%) Impact 0.50 (12%) Druggability 0.40 (10%) Safety 0.30 (8%) Competition 0.35 (6%) Data Avail. 0.35 (5%) Reproducible 0.35 (5%) KG Connect 0.50 (8%) 0.410 composite
7 citations 7 with PMID 7 medium Validation: 0% 5 supporting / 2 opposing
For (5)
5
2
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
2
5
MECH 2CLIN 0GENE 5EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
Dynamics of RNA Polymerase II Pausing and Bivalent…SupportingGENECell Rep MEDIUM2017-PMID:28793256-
Polycomb- and REST-associated histone deacetylases…SupportingMECHElife MEDIUM2014-PMID:25250711-
Epigenetic marks define the lineage and differenti…SupportingGENEStem Cells Dev MEDIUM2013-PMID:23379639-
An Evolutionarily Conserved Function of Polycomb S…SupportingGENECancer Cell MEDIUM2019-PMID:31564637-
Kabuki syndrome stem cell models reveal locus spec…SupportingGENEHum Mol Genet MEDIUM2022-PMID:35640156-
Bivalent chromatin is strongly tied to CNS develop…OpposingMECHGenes Dev MEDIUM2025-PMID:39880657-
RNA polymerase pausing and bivalent H3 methylation…OpposingGENECell Rep MEDIUM2017-PMID:28793256-
Legacy Card View — expandable citation cards

Supporting Evidence 5

Dynamics of RNA Polymerase II Pausing and Bivalent Histone H3 Methylation during Neuronal Differentiation in B… MEDIUM
Dynamics of RNA Polymerase II Pausing and Bivalent Histone H3 Methylation during Neuronal Differentiation in Brain Development.
Cell Rep · 2017 · PMID:28793256
Polycomb- and REST-associated histone deacetylases are independent pathways toward a mature neuronal phenotype… MEDIUM
Polycomb- and REST-associated histone deacetylases are independent pathways toward a mature neuronal phenotype.
Elife · 2014 · PMID:25250711
Epigenetic marks define the lineage and differentiation potential of two distinct neural crest-derived interme… MEDIUM
Epigenetic marks define the lineage and differentiation potential of two distinct neural crest-derived intermediate odontogenic progenitor populations.
Stem Cells Dev · 2013 · PMID:23379639
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Ena… MEDIUM
An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.
Cancer Cell · 2019 · PMID:31564637
Kabuki syndrome stem cell models reveal locus specificity of histone methyltransferase 2D (KMT2D/MLL4). MEDIUM
Hum Mol Genet · 2022 · PMID:35640156

Opposing Evidence 2

Bivalent chromatin is strongly tied to CNS development; evidence that unresolved bivalency at neurodevelopment… MEDIUM
Bivalent chromatin is strongly tied to CNS development; evidence that unresolved bivalency at neurodevelopment genes causes adult neurodegeneration remains indirect.
Genes Dev · 2025 · PMID:39880657
RNA polymerase pausing and bivalent H3 methylation are dynamic during neuronal differentiation, suggesting dev… MEDIUM
RNA polymerase pausing and bivalent H3 methylation are dynamic during neuronal differentiation, suggesting developmental timing complexity rather than a simple failure state.
Cell Rep · 2017 · PMID:28793256
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-20 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Novel Therapeutic Hypotheses: Epigenetic Signatures in Neurodegeneration

Hypothesis 1: REST Complex Dysregulation as a Master Epigenetic Switch Across AD, PD, and ALS

Description: The RE1-Silencing Transcription factor (REST) normally protects neurons by repressing pro-apoptotic and oxidative stress genes through recruitment of CoREST complexes containing HDAC1/2 and G9a. In neurodegenerative diseases, REST is paradoxically sequestered in the cytoplasm (in AD) or downregulated (in ALS), leading to derepression of target genes and histone hyperacetylation at neuronal promoters

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Epigenetic Hypotheses in Neurodegeneration

Hypothesis 1: REST Complex Dysregulation

Specific Weaknesses

  • Mechanistic conflation across diseases: The hypothesis treats three distinct molecular phenomena—REST cytoplasmic sequestration (AD), REST downregulation (ALS), and "transcriptional repression alterations" (PD)—as amenable to a single therapeutic intervention. This ignores fundamental mechanistic differences in how REST function is compromised.
  • Evidence quality disparity: The AD-REST evidence (Lu et al.) derives from postmortem tissue corre
  • 🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

    Drug Development Feasibility Assessment: Epigenetic Hypotheses in Neurodegeneration

    Executive Summary

    After critical evaluation, the seven hypotheses range from moderately actionable (H6: Senolytic-epigenetic combination) to essentially undruggable (H7: N-formylmethionine pathway). The primary bottleneck across most targets is not identifying compounds, but achieving cell-type-specific CNS delivery and demonstrating target engagement in relevant tissues. Below I provide detailed drug development realities for each hypothesis.

    Hypothesis 1: REST Complex Dysregu

    Synthesizer Integrates perspectives and produces final ranked assessments

    Price History

    0.410.430.45 0.46 0.39 2026-04-242026-04-262026-04-28 Market PriceScoreevidencedebate 8 events
    7d Trend
    Rising
    7d Momentum
    ▲ 8.3%
    Volatility
    Medium
    0.0279
    Events (7d)
    8

    Clinical Trials (0)

    No clinical trials data available

    📚 Cited Papers (6)

    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet
    No extracted figures yet

    📅 Citation Freshness Audit

    Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

    No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

    📙 Related Wiki Pages (0)

    No wiki pages linked to this hypothesis yet.

    ࢐ Browse all wiki pages

    ⚔ Arena Performance

    No arena matches recorded yet. Browse Arenas
    → Browse all arenas & tournaments

    📊 Resource Economics & ROI

    Moderate Efficiency Resource Efficiency Score
    0.50
    32.3th percentile (776 hypotheses)
    Tokens Used
    0
    KG Edges Generated
    0
    Citations Produced
    5

    Cost Ratios

    Cost per KG Edge
    0.00 tokens
    Lower is better (baseline: 2000)
    Cost per Citation
    0.00 tokens
    Lower is better (baseline: 1000)
    Cost per Score Point
    0.00 tokens
    Tokens / composite_score

    Score Impact

    Efficiency Boost to Composite
    +0.050
    10% weight of efficiency score
    Adjusted Composite
    0.460

    How Economics Pricing Works

    Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

    High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

    Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

    Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

    📋 Reviews View all →

    Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

    💬 Discussion

    No DepMap CRISPR Chronos data found for Bivalent Domain Resolution.

    Run python3 scripts/backfill_hypothesis_depmap.py to populate.

    No curated ClinVar variants loaded for this hypothesis.

    Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

    🔍 Search ClinVar for Bivalent Domain Resolution →
    Loading history…

    ⚖️ Governance History

    No governance decisions recorded for this hypothesis.

    Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

    Browse all governance decisions →

    KG Entities (6)

    DNA Methylation ClockH3K9me3 HeterochromatinPolycomb-to-Trithorax Switch atRESTSenescence-Associated Epigenetic Phenotyneurodegeneration

    Related Hypotheses

    Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming in Neurodegeneration
    Score: 0.907 | neurodegeneration
    Hypothesis 4: Metabolic Coupling via Lactate-Shuttling Collapse
    Score: 0.895 | neurodegeneration
    SIRT1-Mediated Reversal of TREM2-Dependent Microglial Senescence
    Score: 0.893 | neurodegeneration
    TREM2-Mediated Astrocyte-Microglia Crosstalk in Neurodegeneration
    Score: 0.892 | neurodegeneration
    Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Transition Restoration
    Score: 0.887 | neurodegeneration

    Estimated Development

    Estimated Cost
    $0
    Timeline
    0 months

    🧪 Falsifiable Predictions (2)

    2 total 0 confirmed 0 falsified
    IF bivalent domain resolution fails at neurodevelopment genes in neurodegeneration, THEN ChIP-seq will show significantly higher co-occupancy of H3K4me3 and H3K27me3 at these loci in prefrontal cortex tissue from Alzheimer's disease cases compared to age-matched controls.
    pending conf: 0.45
    Expected outcome: ≥30% increase in bivalent domain peaks at neurodevelopment genes (GO:0007422, GO:0048666) in AD prefrontal cortex (Brodmann area 9) relative to controls, detectable via ChIP-seq with MACS2 peak calling
    Falsified by: Bivalent domain co-occupancy at neurodevelopment genes does not differ between AD cases and controls (difference <15%, p > 0.05 by Mann-Whitney U test)
    Method: Retrospective case-control study using post-mortem prefrontal cortex (Brodmann area 9) from NIH Brain Biobank: n≥40 AD cases (Braak stage V-VI, age 70-90, PMI <24h) vs n≥40 cognitively normal controls matched for age and post-mortem interval. H3K4me3 and H3K27me3 ChIP-seq with ENCODE standards, analyzed via MACS2 and ChIPseeker
    IF bivalent domain resolution failure contributes to neurodegeneration, THEN siRNA-mediated knockdown of the H3K27me3 demethylase KDM6B in iPSC-derived cortical neurons will dysregulate neurodevelopment genes that normally resolve bivalency during differentiation.
    pending conf: 0.35
    Expected outcome: ≥50% of neurodevelopment genes (n≥200 with bivalent domains in undifferentiated NPCs) will show ≥2-fold expression change after KDM6B knockdown at day 30 of differentiation, with retention of both H3K4me3 and H3K27me3 marks as measured by ChIP-qPCR
    Falsified by: Neurodevelopment gene expression and bivalent domain occupancy remain unchanged after KDM6B knockdown (change <1.5-fold, p > 0.05 by paired t-test)
    Method: Prospective in vitro study: iPSC lines (n=3, fromND00027, ND00030, ND00044, NIMHStem) differentiated to cortical neurons via dual-SMAD inhibition protocol. Transfection with KDM6B siRNA (Horizon, L-004936-00-0005) vs non-targeting control at day 15. RNA-seq (Illumina NovaSeq) and ChIP-qPCR at day 30. Genes bivalent in NPCs defined by existing H3K4me3/H3K27me3 ChIP-seq from hNPC stage (GSE113660)

    Knowledge Subgraph (5 edges)

    implicates in (5)

    Senescence-Associated Epigenetic PhenotypeneurodegenerationRESTneurodegenerationH3K9me3 HeterochromatinneurodegenerationPolycomb-to-Trithorax Switch atneurodegenerationDNA Methylation Clockneurodegeneration

    Mechanism Pathway for Bivalent Domain Resolution

    Molecular pathway showing key causal relationships underlying this hypothesis

    graph TD
        Senescence_Associated_Epi["Senescence-Associated Epigenetic Phenotype"] -->|implicates in| neurodegeneration["neurodegeneration"]
        REST["REST"] -->|implicates in| neurodegeneration_1["neurodegeneration"]
        H3K9me3_Heterochromatin["H3K9me3 Heterochromatin"] -->|implicates in| neurodegeneration_2["neurodegeneration"]
        Polycomb_to_Trithorax_Swi["Polycomb-to-Trithorax Switch at"] -->|implicates in| neurodegeneration_3["neurodegeneration"]
        DNA_Methylation_Clock["DNA Methylation Clock"] -->|implicates in| neurodegeneration_4["neurodegeneration"]
        style Senescence_Associated_Epi fill:#4fc3f7,stroke:#333,color:#000
        style neurodegeneration fill:#ef5350,stroke:#333,color:#000
        style REST fill:#ce93d8,stroke:#333,color:#000
        style neurodegeneration_1 fill:#ef5350,stroke:#333,color:#000
        style H3K9me3_Heterochromatin fill:#4fc3f7,stroke:#333,color:#000
        style neurodegeneration_2 fill:#ef5350,stroke:#333,color:#000
        style Polycomb_to_Trithorax_Swi fill:#4fc3f7,stroke:#333,color:#000
        style neurodegeneration_3 fill:#ef5350,stroke:#333,color:#000
        style DNA_Methylation_Clock fill:#4fc3f7,stroke:#333,color:#000
        style neurodegeneration_4 fill:#ef5350,stroke:#333,color:#000

    3D Protein Structure

    🧬 BIVALENT — Search for structure Click to search RCSB PDB
    🔍 Searching RCSB PDB for BIVALENT structures...
    Querying Protein Data Bank API

    Source Analysis

    Comparative epigenetic signatures: DNA methylation age acceleration and histone modifications across AD, PD, and ALS

    neurodegeneration | 2026-04-18 | completed

    Community Feedback

    0 0 upvotes · 0 downvotes
    💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

    No comments yet. Be the first to comment!

    View all feedback (JSON)

    Same Analysis (5)

    Senescence-Associated Epigenetic Phenotype (SEP)
    Score: 0.62 · Senescence-Associated Epigenetic Phenotype
    REST Complex Dysregulation as Master Epigenetic Switch
    Score: 0.57 · REST
    H3K9me3 Heterochromatin Loss at Pericentromeric Repeats
    Score: 0.56 · H3K9me3 Heterochromatin
    Polycomb-to-Trithorax Switch at Synaptic Plasticity Genes
    Score: 0.53 · Polycomb-to-Trithorax Switch at
    DNA Methylation Clock Drift at Glial Promoters
    Score: 0.48 · DNA Methylation Clock
    → View all analysis hypotheses
    Public annotations (0)Annotate on Hypothes.is →
    No public annotations yet.